1. Medtech Insight
  2. >>Digital Technologies

New Frontier: COVID-19 Crisis Opens Door For Dexcom, Abbott To Bring CGMs Into Hospitals For First Time

 
• By Marion Webb

Dexcom and Abbott’s permission by US regulators to bring their continuous glucose monitoring devices directly to hospitals for remote monitoring of COVID-19 patients could open up a new market opportunity post-pandemic.

DexcomG6 Full Family

The US Food and Drug Administration has given Dexcom Inc. and Abbott Laboratories Inc. permission to bring their continuous blood glucose monitoring (CGM) systems into hospitals during the COVID-19 pandemic.

Health care workers will be able to use Dexcom’s G6 CGM and Abbott’s FreeStyle Libre 14-day system to remotely monitor patients with diabetes, which helps minimize their exposure to COVID-19...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.